These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

290 related articles for article (PubMed ID: 30426615)

  • 21. Targeting Phosphorylation of Y-Box-Binding Protein YBX1 by TAS0612 and Everolimus in Overcoming Antiestrogen Resistance.
    Shibata T; Watari K; Kawahara A; Sudo T; Hattori S; Murakami Y; Izumi H; Itou J; Toi M; Akiba J; Akagi Y; Tanaka M; Kuwano M; Ono M
    Mol Cancer Ther; 2020 Mar; 19(3):882-894. PubMed ID: 31879363
    [TBL] [Abstract][Full Text] [Related]  

  • 22. YBX1/YB-1 induces partial EMT and tumourigenicity through secretion of angiogenic factors into the extracellular microenvironment.
    Gopal SK; Greening DW; Mathias RA; Ji H; Rai A; Chen M; Zhu HJ; Simpson RJ
    Oncotarget; 2015 May; 6(15):13718-30. PubMed ID: 25980435
    [TBL] [Abstract][Full Text] [Related]  

  • 23. As a downstream target of the AKT pathway, NPTX1 inhibits proliferation and promotes apoptosis in hepatocellular carcinoma.
    Zhao Y; Yu Y; Zhao W; You S; Feng M; Xie C; Chi X; Zhang Y; Wang X
    Biosci Rep; 2019 Jun; 39(6):. PubMed ID: 31113871
    [TBL] [Abstract][Full Text] [Related]  

  • 24. The Role of EGFR, Hepatocyte Growth Factor Receptor (c-Met), c-ErbB2 (HER2-neu) and Clinicopathological Parameters in the Pathogenesis and Prognosis of Chordoma.
    Tosuner Z; Bozkurt SU; Kiliç T; Yilmaz B
    Turk Patoloji Derg; 2017; 33(2):112-120. PubMed ID: 28272674
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Leukocyte Cell-Derived Chemotaxin 2 Retards Non-Small Cell Lung Cancer Progression Through Antagonizing MET and EGFR Activities.
    Hung WY; Chang JH; Cheng Y; Chen CK; Chen JQ; Hua KT; Cheng CW; Hsiao M; Chung CL; Lee WJ; Chien MH
    Cell Physiol Biochem; 2018; 51(1):337-355. PubMed ID: 30453282
    [TBL] [Abstract][Full Text] [Related]  

  • 26. High YBX1 expression indicates poor prognosis and promotes cell migration and invasion in nasopharyngeal carcinoma.
    Zhou LL; Ni J; Feng WT; Yao R; Yue S; Zhu YN; Tang HY; Lv LY; Feng JF; Zhu WG
    Exp Cell Res; 2017 Dec; 361(1):126-134. PubMed ID: 29024700
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Deoxycholic acid activates epidermal growth factor receptor and promotes intestinal carcinogenesis by ADAM17-dependent ligand release.
    Dong W; Liu L; Dou Y; Xu M; Liu T; Wang S; Zhang Y; Deng B; Wang B; Cao H
    J Cell Mol Med; 2018 Sep; 22(9):4263-4273. PubMed ID: 29956475
    [TBL] [Abstract][Full Text] [Related]  

  • 28. RAN and YBX1 are required for cell proliferation and IL-4 expression and linked to poor prognosis in oral squamous cell carcinoma.
    Che X; Liu M; Li D; Li Z; Guo J; Jia R
    Exp Cell Res; 2021 Sep; 406(2):112767. PubMed ID: 34364882
    [TBL] [Abstract][Full Text] [Related]  

  • 29. The role of epidermal growth factor receptor in chordoma pathogenesis: a potential therapeutic target.
    Shalaby A; Presneau N; Ye H; Halai D; Berisha F; Idowu B; Leithner A; Liegl B; Briggs TR; Bacsi K; Kindblom LG; Athanasou N; Amary MF; Hogendoorn PC; Tirabosco R; Flanagan AM
    J Pathol; 2011 Feb; 223(3):336-46. PubMed ID: 21171079
    [TBL] [Abstract][Full Text] [Related]  

  • 30. HCRP-1 regulates EGFR-AKT-BIM-mediated anoikis resistance and serves as a prognostic marker in human colon cancer.
    Chen F; Zhang L; Wu J; Huo F; Ren X; Zheng J; Pei D
    Cell Death Dis; 2018 Dec; 9(12):1176. PubMed ID: 30518879
    [TBL] [Abstract][Full Text] [Related]  

  • 31. KMT2D-mediated H3K4me1 recruits YBX1 to facilitate triple-negative breast cancer progression through epigenetic activation of c-Myc.
    Yao B; Xing M; Zeng X; Zhang M; Zheng Q; Wang Z; Peng B; Qu S; Li L; Jin Y; Li H; Yuan H; Zhao Q; Ma C
    Clin Transl Med; 2024 Jul; 14(7):e1753. PubMed ID: 38967349
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Osteoglycin (OGN) reverses epithelial to mesenchymal transition and invasiveness in colorectal cancer via EGFR/Akt pathway.
    Hu X; Li YQ; Li QG; Ma YL; Peng JJ; Cai SJ
    J Exp Clin Cancer Res; 2018 Mar; 37(1):41. PubMed ID: 29499765
    [TBL] [Abstract][Full Text] [Related]  

  • 33. C1QBP Regulates YBX1 to Suppress the Androgen Receptor (AR)-Enhanced RCC Cell Invasion.
    Yue D; Wang Y; Sun Y; Niu Y; Chang C
    Neoplasia; 2017 Feb; 19(2):135-144. PubMed ID: 28107702
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Selective sorting and secretion of hY4 RNA fragments into extracellular vesicles mediated by methylated YBX1 to promote lung cancer progression.
    Li C; Wang W; Sun Y; Ni Y; Qin F; Li X; Wang T; Guo M; Sun G
    J Exp Clin Cancer Res; 2022 Apr; 41(1):136. PubMed ID: 35410432
    [TBL] [Abstract][Full Text] [Related]  

  • 35. PLAUR Confers Resistance to Gefitinib Through EGFR/P-AKT/Survivin Signaling Pathway.
    Zhou J; Kwak KJ; Wu Z; Yang D; Li J; Chang M; Song Y; Zeng H; Lee LJ; Hu J; Bai C
    Cell Physiol Biochem; 2018; 47(5):1909-1924. PubMed ID: 29961070
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Dysregulated Expression of the MicroRNA miR-137 and Its Target YBX1 Contribute to the Invasive Characteristics of Malignant Pleural Mesothelioma.
    Johnson TG; Schelch K; Cheng YY; Williams M; Sarun KH; Kirschner MB; Kao S; Linton A; Klebe S; McCaughan BC; Lin RCY; Pirker C; Berger W; Lasham A; van Zandwijk N; Reid G
    J Thorac Oncol; 2018 Feb; 13(2):258-272. PubMed ID: 29113949
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Erlotinib inhibits growth of a patient-derived chordoma xenograft.
    Siu IM; Ruzevick J; Zhao Q; Connis N; Jiao Y; Bettegowda C; Xia X; Burger PC; Hann CL; Gallia GL
    PLoS One; 2013; 8(11):e78895. PubMed ID: 24260133
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Transcriptional activation of NANOG by YBX1 promotes lung cancer stem-like properties and metastasis.
    Guo T; Kong J; Liu Y; Li Z; Xia J; Zhang Y; Zhao S; Li F; Li J; Gu C
    Biochem Biophys Res Commun; 2017 May; 487(1):153-159. PubMed ID: 28400280
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Rationale for the advancement of PI3K pathway inhibitors for personalized chordoma therapy.
    Michmerhuizen NL; Owen JH; Heft Neal ME; Mann JE; Leonard E; Wang J; Zhai J; Jiang H; McHugh JB; Brenner JC; Prince MEP
    J Neurooncol; 2020 Mar; 147(1):25-35. PubMed ID: 32067197
    [TBL] [Abstract][Full Text] [Related]  

  • 40. YBX1 Promotes MSC Osteogenic Differentiation by Activating the PI3K/AKT Pathway.
    Chen J; Liu Z; Zhang H; Yang Y; Zeng H; Zhong R; Lai S; Liao H
    Curr Stem Cell Res Ther; 2023; 18(4):513-521. PubMed ID: 35929633
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 15.